Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [2 ]
Kueenburg, Elisabeth [3 ]
机构：
[1] Priothera SAS, Valkenburg, Netherlands
[2] Priothera SAS, Basel, Switzerland
[3] Priothera SAS, St Louis, France
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-193899
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5774 / 5775
页数：2
相关论文
共 50 条
  • [1] Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
    Ho, Yu Liu
    Gorycki, Pete
    Ferron-Brady, Geraldine
    Martin, Paul
    Vlasakakis, Georgios
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [2] Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters
    Barth, Aline
    Perry, Caroline R.
    Shabbir, Shaila
    Zamek-Gliszczynski, Maciej J.
    Thomas, Sebin
    Dumont, Etienne F.
    Brimhall, Darin B.
    Nguyen, Dung
    Srinivasan, Meenakshi
    Swift, Brandon
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (04): : 647 - 661
  • [3] SYSTEMATIC ASSESSMENT OF INTESTINAL METABOLISM AND DEGREE OF INHIBITION IN DRUG-DRUG INTERACTIONS CAUSED BY INHIBITION OF CYP3A
    Nakamura, M.
    Koh, S.
    Hisaka, A.
    Suzuki, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S35 - S35
  • [4] Quantitative prediction of CYP3A induction-mediated drug-drug interactions in clinical practice
    Tsutsui, Haruka
    Kato, Motohiro
    Kuramoto, Shino
    Yoshinari, Kouichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 57
  • [5] CYP3A mediated drug-drug interactions: Contribution of CYP 3A4 and CYP 3A5
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1057 - 1057
  • [6] A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions
    Takashi Yoshikado
    Kazuya Maeda
    Sawako Furihata
    Hanano Terashima
    Takeshi Nakayama
    Keiko Ishigame
    Kazunobu Tsunemoto
    Hiroyuki Kusuhara
    Ken-ichi Furihata
    Yuichi Sugiyama
    Pharmaceutical Research, 2017, 34 : 1570 - 1583
  • [7] A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions
    Yoshikado, Takashi
    Maeda, Kazuya
    Furihata, Sawako
    Terashima, Hanano
    Nakayama, Takeshi
    Ishigame, Keiko
    Tsunemoto, Kazunobu
    Kusuhara, Hiroyuki
    Furihata, Ken-ichi
    Sugiyama, Yuichi
    PHARMACEUTICAL RESEARCH, 2017, 34 (08) : 1570 - 1583
  • [8] CYP3A and drug interactions
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1212): : 54 - 55
  • [9] UNDERSTANDING THE ROLE OF CYP3A IN THE METABOLISM OF KINASE INHIBITORS MARKETED IN THE PAST DECADE TO BETTER MANAGE THE RISK OF CLINICAL DRUG-DRUG INTERACTIONS
    Yu, Jingjing
    Argon, Sophie
    Owens, Katie
    Petrie, Ichiko
    Ragueneau-Majlessi, Isabelle
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [10] Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
    Bleasby, Kelly
    Houle, Robert
    Hafey, Michael
    Lin, Meihong
    Guo, Jingjing
    Lu, Bing
    Sanchez, Rosa I.
    Fillgrove, Kerry L.
    VIRUSES-BASEL, 2021, 13 (08):
12345